MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 134 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $229,770,281 | -32.1% | 1,573,338 | +7.4% | 0.01% | -25.0% |
| Q2 2023 | $338,535,582 | -1.5% | 1,465,522 | +3.3% | 0.01% | -11.1% |
| Q1 2023 | $343,566,591 | -6.5% | 1,418,173 | +12.0% | 0.01% | -10.0% |
| Q4 2022 | $367,565,343 | +350.9% | 1,266,375 | +1.0% | 0.01% | +400.0% |
| Q3 2022 | $81,517,000 | -7.6% | 1,254,305 | +1.8% | 0.00% | 0.0% |
| Q2 2022 | $88,186,000 | -26.1% | 1,231,983 | +1.4% | 0.00% | -33.3% |
| Q1 2022 | $119,257,000 | +25.3% | 1,215,413 | +8.2% | 0.00% | +50.0% |
| Q4 2021 | $95,168,000 | +11.3% | 1,123,061 | +4.8% | 0.00% | 0.0% |
| Q3 2021 | $85,497,000 | -16.4% | 1,071,530 | +2.1% | 0.00% | -33.3% |
| Q2 2021 | $102,213,000 | -12.4% | 1,049,310 | +5.2% | 0.00% | 0.0% |
| Q1 2021 | $116,713,000 | +18.2% | 997,809 | +12.3% | 0.00% | 0.0% |
| Q4 2020 | $98,765,000 | +8.5% | 888,418 | +15.9% | 0.00% | 0.0% |
| Q3 2020 | $91,006,000 | -1.8% | 766,504 | -6.3% | 0.00% | 0.0% |
| Q2 2020 | $92,630,000 | +66.2% | 817,929 | -2.0% | 0.00% | +50.0% |
| Q1 2020 | $55,725,000 | -22.1% | 834,701 | +6.3% | 0.00% | 0.0% |
| Q4 2019 | $71,561,000 | +5.1% | 785,441 | -0.6% | 0.00% | -33.3% |
| Q3 2019 | $68,108,000 | -13.5% | 789,939 | +5.2% | 0.00% | 0.0% |
| Q2 2019 | $78,694,000 | -19.6% | 750,826 | -3.9% | 0.00% | -25.0% |
| Q1 2019 | $97,862,000 | +16.2% | 781,276 | +4.6% | 0.00% | 0.0% |
| Q4 2018 | $84,200,000 | -44.3% | 746,976 | +5.8% | 0.00% | -33.3% |
| Q3 2018 | $151,243,000 | +16.9% | 706,318 | +52.7% | 0.01% | +20.0% |
| Q2 2018 | $129,400,000 | +286.2% | 462,654 | +61.3% | 0.01% | +400.0% |
| Q1 2018 | $33,506,000 | +33.0% | 286,884 | +4.6% | 0.00% | 0.0% |
| Q4 2017 | $25,184,000 | +290.3% | 274,359 | +91.3% | 0.00% | – |
| Q3 2017 | $6,452,000 | +399.8% | 143,443 | +80.7% | 0.00% | – |
| Q2 2017 | $1,291,000 | -5.6% | 79,384 | -10.7% | 0.00% | – |
| Q1 2017 | $1,368,000 | +3.2% | 88,871 | -0.1% | 0.00% | – |
| Q4 2016 | $1,325,000 | +2.6% | 88,917 | -12.7% | 0.00% | – |
| Q3 2016 | $1,291,000 | – | 101,833 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |